Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Understanding the SARS-Cov2 epidemic is a major public health issue, both in the community and in the hospital sector. Because of their central position in the management of patients infected with COVID-19, hospital staff may be considered at high risk of infection. The development of serological tests makes it possible to reliably document a contamination, symptomatic or not, that is more than 3 weeks old. These tests, combined with clinical questioning of the symptoms, make it possible to determine the proportion of asymptomatic infections whose impact in the transmission of this disease appears to be major. The duration of the presence of the antibodies that are hoped to neutralize after infection with CoV2-SARS remains uncertain. Documenting the evolution of antibody levels and their monitoring in a population at high risk of re-exposure to CoV2-SARS is a major issue in understanding this disease and in assessing the risk of infection among healthcare workers.
Description: Number of contaminated personnel by occupational category and department on day 1.
Measure: Number of contaminated personnel Time: day 1Description: Number of contaminated personnel by professional category and by service at month 3 a by serological test
Measure: Number of contaminated personnel Time: month 3Description: Number of contaminated personnel by professional category and by service at month 6 a by serological test
Measure: Number of contaminated personnel Time: month 6Description: Number of symptomatic staff by occupational category and service at Month 3 with positive RT-PCR Cov2 SARS
Measure: Number of symptomatic staff by occupational category and service Time: month 3Description: Number of symptomatic staff by occupational category and service at Month 6 with positive RT-PCR Cov2 SARS
Measure: Number of symptomatic staff by occupational category and service Time: month 6Description: Number of contaminated personnel with effective protection: evolution of the antibody index at day 1, month 3 and month 6
Measure: Number of contaminated personnel with effective protection Time: evolution at day 1, month 3 and month 6Description: comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies between two stitch dates.
Measure: comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies Time: month 6Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports